New York Times reporting confirms that demand for COVID-19 vaccines has fallen sharply and that Moderna’s revenue declined in tandem. The company has increased development of mRNA-based cancer candidates. Analyses from progressive, conservative, libertarian, and critical viewpoints differ on the causes, implications, and prior history of the oncology program.